Paired Ends | GenomeWeb

Paired Ends

Premium

Oxford Nanopore has appointed Peter Allen to non-executive director of the board. He currently serves as non-executive chairman on the boards of ProStrakan Group, Chroma Therapeutics, and Proximagen Neuroscience. Previously, he served as chief financial officer for Abacus Group and Celltech Group. He was also the deputy CEO of Celltech until the company was sold in 2004. Allen succeeds Riccardo Pigliucci, who is retiring.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Four Republican lawmakers urge President-elect Donald Trump to keep Francis Collins as NIH director, Stat News reports.

In Genome Research this week: Platinum variant catalog, algorithmic strategy for upgrading fragmented assemblies, and more.

Sequencing of a 10,000-year-old mummy leads to its repatriation to the Fallon Paiute-Shoshone Tribe, Nature News reports.

The final text of the bill to reauthorize the America COMPETES Act might smooth over the differences between NSF and the House science committee, ScienceInsider says.